Open AccessDecline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis
Author(s) -
Peter L. Havens,
Charles B. Stephensen,
Marta D. Van Loan,
Gertrud U. Schuster,
Leslie R. Woodhouse,
Patricia M. Flynn,
Catherine M. Gordon,
Cynthia G. Pan,
Brandy Rutledge,
Nancy Liu,
Craig M. Wilson,
Rohan Hazra,
Sybil Hosek,
Peter L. Anderson,
Sharon M. Seifert,
Bill G. Kapogiannis,
Kathleen Mulligan
Publication year - 2016
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciw765
Subject(s) - tenofovir , emtricitabine , medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , virology , viral load
We aimed to define the relative importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom